cas 79257-61-7|| where to buy N-(3,5-dimethoxyphenyl)acetamide

Nom du produit:N-(3,5-dimethoxyphenyl)acetamide

IUPAC Name:N-(3,5-dimethoxyphenyl)acetamide

Unité d'emballage	Stock disponible	Prix($)	Quantité
CM312360-1g	in stock	ƋǆȌ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 79257-61-7 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:79257-61-7; Formule moléculaire:C10H13NO3; Point de fusion:-; Code SMILES:CC(NC1=CC(OC)=CC(OC)=C1)=O; Densité:

: Numéro de catalogue:CM312360; Poids moléculaire:195.22; Point d'ébullition:; N° Mdl:MFCD00541138; Stockage:

: Benzenes; Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

: Infigratinib; Sept. 06, 2023, positive feedback from the U.S. FDA and the EU EMA on key elements of the trial design for PROPEL3, its pivotal Phase 3 study of infigratinib in children with achondroplasia.
Achondroplasia is the most common cause of disproportionate short stature, affecting approximately 55,000 people in the United States and European Union, including up to 10,000 children and adolescents with open growth plates. Achondroplasia impacts overall health and quality of life, leading to medical complications such as obstructive sleep apnea, middle ear dysfunction, kyphosis, and spinal stenosis. The condition is uniformly caused by an activating mutation in FGFR3.
Infigratinib is an oral small molecule designed to inhibit FGFR3 and target achondroplasia at its source. It is incredibly exciting that infigratinib has the potential to become the first effective oral treatment option to improve growth, enhance functionality and decrease complications.